gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Belantamab targets BCMA on tumor cells; its afucosylated Fc binds CD16a on NK cells to trigger ADCC against BCMA+ cells. CD16a-expressing cells are not targeted or killed by the drug.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated ADCC engagement; enhanced by afucosylated IgG1
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05714839
disease_id_num_tar_ref
1658
drug_id_num_tar_ref
4484